Skip to main content
Fig. 4 | BMC Medical Research Methodology

Fig. 4

From: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade®

Fig. 4

Risk of non-infectious uveitis (NIU) among patients with inflammatory bowel diseases (IBD)

Key – PS: propensity score, OT: on-treatment, ITT: intention-to-treat, T: Remicade® new users with IBD, C: golimumab, certolizumab pegol, ustekinumab, or vedolizumab new users with IBD, IR: incidence rate, PYs: person-years, CCAE: Merative™ MarketScan® Commercial Database, Optum® EHR: Optum® De-Identified Electronic Health Record, Pharmetrics: IQVIA Adjudicated Health Plan Claims Data

Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us